2. Search Result
Search Result
Results for "

IP6K1

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

1

Recombinant Proteins

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-171099
    SC-919

    LI-2124

    		 IPK Superfamily Cardiovascular Disease Endocrinology
    SC-919 is an orally active IP6K inhibitor, with an IC50 of < 5.2 nM against IP6K1, < 3.8 nM against IP6K2, and 0.65 nM against IP6K3. By inhibiting the activity of IP6K, SC-919 reduces intracellular IP7 levels, thereby suppressing XPR1-mediated cellular phosphate efflux. SC-919 increases intracellular phosphate and ATP levels while reducing phosphate entry into the bloodstream, thus decreasing plasma phosphate levels. SC-919 can be used in research related to chronic kidney disease and hyperphosphatemia .
    SC-919
  • HY-110079
    TNP

    		IPK Superfamily Cancer
    TNP is a competitive, reversible inhibitor of IP6K1 and IP3K, with IC50s of 0.55 μM and 10.2 μM for IP6K1 and IP3K, respectively. TNP competitively binds to the ATP binding site of IP6K, inhibits the generation of 5-IP7, and thus relieves the inhibition of 5-IP7 on the AKT signaling pathway. TNP can enhance insulin sensitivity and promote thermogenesis in adipose tissue. TNP cannot effectively pass through the blood-brain barrier and is mainly used in the study of obesity, type 2 diabetes, and metabolic syndrome. However, TNP also inhibits CYP3A4 and may need further optimization[1][2][3].
    TNP
  • HY-150607
    UNC7467

    		IPK Superfamily Others
    UNC7467 is a potent IP6K inhibitor with values of 4.9, 8.9 and 1320 nM for IP6K2, IP6K1 and IP6K6, respectively. UNC7467 reduces levels of inositol pyrophosphates. UNC7467 can be used for obesity research .
    UNC7467
  • HY-153530
    LI-2242

    		IPK Superfamily Neurological Disease Metabolic Disease
    LI-2242 is an inositol hexakisphosphate kinase (IP6K) inhibitor. LI-2242 has inhibition effect for IP6K1, IP6K2, IP6K3 and IPMK with IC50 values of 31 nM, 42 nM, 8.7 nM and 1944 nM, respectively. LI-2242 can be used for thew research of type II diabetes, obesity, metabolic complications, venous thrombosis, and psychiatric disorders .
    LI-2242
  • HY-RS26193
    Ip6k1 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Ip6k1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ip6k1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ip6k1 Rat Pre-designed siRNA Set A
    Ip6k1 Rat Pre-designed siRNA Set A
  • HY-RS19698
    Ip6k1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Ip6k1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ip6k1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ip6k1 Mouse Pre-designed siRNA Set A
    Ip6k1 Mouse Pre-designed siRNA Set A
  • HY-RS06861
    IP6K1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    IP6K1 Human Pre-designed siRNA Set A contains three designed siRNAs for IP6K1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    IP6K1 Human Pre-designed siRNA Set A
    IP6K1 Human Pre-designed siRNA Set A
  • HY-122706A
    IP6K2-IN-2

    		IPK Superfamily Metabolic Disease
    IP6K2-IN-2 (Compound 6) is an IP6K2 inhibitor, with IC50 values of 0.58 μM (IP6K2), 0.86 μM (IP6K1) and 3.08 μM (IP6K3). IP6K2-IN-2 can be used in research of obesity .
    IP6K2-IN-2
  • HY-185141
    IP6K-IN-2

    		IPK Superfamily Neurological Disease
    IP6K-IN-2 is an inositol hexakisphosphate kinase (IP6K1) inhibitor that inhibits IP6K1 enzyme activity with an IC50 value of 110 nM. IP6K-IN-2 can be used for the research of neurological disease and CNS disorders .
    IP6K-IN-2
  • HY-161032
    IP6K2-IN-1

    		IPK Superfamily Inflammation/Immunology
    IP6K2-IN-1 is a selective flavonoid-based IP6K2 inhibitor with an IC50 value of 0.55 μM . IP6K2-IN-1 shows higher inhibitory potency against IP6K2 than IP6K1 and IP6K3. IP6K2-IN-1 can be utilised as a hit compound for further structural modifications of IP6K2 inhibitors .
    IP6K2-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: